MentalHealthDaily

Brazilian Eating Disorder Guidelines: CBT First for Bulimia and Binge Eating, Fewer Proven Options for Anorexia

by GLOOM

MHD card with an open glowing guideline book on a dark navy background, three colored pathways branching from its spine to three nodes, and stepped translucent evidence tiers at the right edge, illustrating eating disorder treatment guidelines.

New Brazilian Psychiatric Association guidelines put cognitive behavioral therapy (CBT) first for bulimia and binge-eating disorder, with fluoxetine and lisdexamfetamine as the preferred medications. For anorexia, no single therapy has proven best, and drugs play only a small supporting role.1 Research Highlights Binge-eating disorder: clinician-led CBT is first-line and leads to remission of binge eating …

Top-Ranked Treatments for Schizophrenia Aggression: Clozapine, Paliperidone and Olanzapine

by GLOOM

MHD card with an amber network of antipsychotic drug nodes linked to a placebo node over a dark background, with a calming waveform: clozapine, paliperidone, and olanzapine reduced aggression in schizophrenia most, but confidence was low.

A 2026 analysis of 41 randomized studies involving 21,025 adults with schizophrenia found the largest estimated reductions in hostility and aggression for clozapine (standardized mean difference, or SMD, of −0.75), paliperidone (−0.62), and olanzapine (−0.60) vs. placebo.1 Confidence in every comparison was low or very low, the top 3 were not statistically separable, and most …

Right OFC rTMS Improves Memory in Early Schizophrenia

by GLOOM

Editorial card showing a coronal brain section highlighting the right orbitofrontal cortex with a TMS coil, illustrating the first RCT of OFC stimulation in first-episode schizophrenia.

Cognitive impairment in first-episode schizophrenia (FES) is the symptom that does the most work blocking employment, relationships, and independent living — and the symptom current antipsychotics barely move. A 2026 RCT by Hu et al. in Psychological Medicine tested whether 20 sessions of low-frequency rTMS targeting the right orbitofrontal cortex (OFC) could improve cognition where …

Olanzapine for Anorexia: A Promising Treatment Both Systemically & Intranasally (2023 Study)

by GLOOM

Anorexia nervosa (AN), a severe mental disorder characterized by an intense fear of gaining weight and a distorted body image, remains a formidable challenge in psychiatric treatment. Recent research has shone a light on the potential of olanzapine, an atypical antipsychotic, in offering new hope through both systemic and innovative intranasal administration methods in animal …

Top 10 Pharma Drugs & Medications That Cause Weight Gain (2012-2021)

by GLOOM

It is estimated that 40% of U.S. adults are obese – and this figure is projected to continue growing. One potential reason for weight gain and a possible catalyst for obesity is use of pharmaceutical drugs (i.e. medications). Medication-induced weight gain poses a significant challenge in healthcare, affecting both patient well-being and treatment adherence. Key …

Zyprexa and Weight Gain: How It Causes You To Get Fat

by GLOOM

Zyprexa (Olanzapine) is an atypical antipsychotic medication that is approved by the FDA for the treatment of schizophrenia and bipolar disorder. In relatively rare cases, it is used as an augmentation strategy for the treatment of depression. The drug is manufactured by the company Eli Lilly, and has generated billions of dollars in revenue. Despite …

Zyprexa (Olanzapine) Withdrawal Symptoms + How Long Do They Last?

by GLOOM

Zyprexa (Olanzapine) is an atypical antipsychotic drug that is commonly utilized for the treatment of schizophrenia and bipolar disorder. It works more on serotonin receptors than dopamine receptors, but targets both. Although this is a drug that can work well for treating severe mental illnesses, more than 50% of people quit taking it during clinical …